Class summary at a glance.

Every drug in the Opioid Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $89.7Mcombined across class
Total Rx claims: 1.6M934K unique beneficiaries
Generic mfrs (active): 25across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Naloxone

Brand: KLOXXADO · 805K Part D claims (CY24) · 680K beneficiaries · First FDA approval: 1986-09-24

16 generic mfrs 0 plans require PA

Low NADAC$4.09

→

Avg plan cost$9.56

Part D spend $51.0M 2× spread, current vs floor

Class share

57%

of class CY24 spend

View profile →

Naltrexone

Brand: VIVITROL · 748K Part D claims (CY24) · 254K beneficiaries · First FDA approval: 2002-03-22

6 generic mfrs 0 plans require PA

Low NADAC$1.22

→

Avg plan cost$79.33

Part D spend $38.7M 65× spread, current vs floor

Class share

43%

of class CY24 spend

View profile →

Alvimopan

— Part D claims (CY24) · First FDA approval: 2020-12-01

3 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.